Triple-negative breast cancer: new hope for an existing drug
RI-MUHC team takes another step toward precision medicine by targeting a biomarker of CDK4/6 inhibitor efficacy in breast cancer, including triple-negative...
Prescribing personalized lifestyle interventions to improve prostate cancer treatments
David Labbé of the RI-MUHC co-leads a new project recently funded by the Marathon of Hope Cancer Centres...
Researchers find a possible therapeutic target in the “genetic landscape” of aggressive and deadly pediatric brain tumours
A new study reveals that PFA ependymoma brain tumours display...
McGill, industry, CQDM and Brain Canada collaborate for drug discovery
Novel drug could provide hope to those suffering from neuropathic pain and insomnia
Major funding awards for seven RI-MUHC trainees
A Banting Fellowship and six Vanier Scholarships were awarded in 2024
RI-MUHC researchers work to accelerate precision medicine for cancer in Canada
Three additional RI-MUHC research projects funded by the Marathon of Hope Cancer Centres Network
Developing technology for fight against antimicrobial resistance
New treatment under development by researchers Karine Auclair and Andréanne Lupien could potentially treat intracellular infections without...
Annual Clinical Research Day event highlights RI-MUHC services and expertise in clinical trials
The Centre for Innovative Medicine and many other clinical research support teams introduced their skills...
Nada Jabado named 2024 L’Oréal-UNESCO For Women in Science Laureate for North America
Prestigious award honours McGill and RI-MUHC pioneer in the field of pediatric brain tumours
Two RI-MUHC researchers receive funding from the Marathon of Hope Cancer Centres Network
Morag Park, Ph.D. and George Zogopoulos, MD., Ph.D., are two of the four beneficiaries of the Pan-Canadian...